ArticleInfectious agents and cancer2025
Development and validation of a multiplex qPCR method for identification of high-risk genotypes of human papillomavirus.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Development of a multiplex quantitative real-time PCR (qPCR) assay for simultaneous detection of Schistosoma haematobium and high-risk human papillomaviruses.PLoS neglected tropical diseases · 2026Article
- Quantitative Multiplex Digital PCR with Fluorescence-Encoded Nanoreactor Beads.Analytical chemistry · 2026Article
- Development and validation of a quantitative pcr array assay for the detection of viral sequences in breast cancer.Journal, genetic engineering & biotechnology · 2026Article
- Development of an ELISA Test with High Diagnostic Accuracy for SARS-COV-2 Using Recombinant Nucleocapsid Protein Expressed in E. coli.Molecular biotechnology · 2026Article
- Enhanced SfaTnpB enables single-base-specific, one-pot nucleic acid detection for high-sensitivity diagnostics.Nucleic acids research · 2026Article
- Human papillomavirus (HPV) genotypes extended prevalence in the female population from a city in Northern Chile.BMC women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is a significant public health concern, disproportionately affecting women in less developed regions due to limited access to screening and vaccination programs. Despite advancements in cervical cancer prevention and treatment, there remains a need for efficient and cost-effective diagnostic tools. This study aimed to develop a multiplex real-time PCR assay to rapidly and accurately identify 15 human papillomavirus (HPV) genotypes.The primary objective was to design a screening method capable of simultaneously detecting HPV types 16 and 18, which account for over 70% of cervical cancers, as well as other clinically relevant high-risk and probable/possible high-risk. To validate the assay's performance, we compared its results with those obtained using the commercially available INNO-LiPA HPV Genotyping Extra II Assay kit (FujireBio, Tokyo, Japan). The developed assay successfully identified 15 HPV genotypes in a single reaction. Analysis of 150 positive and 40 negative clinical samples demonstrated excellent concordance between the two assays. The in-house real-time PCR test exhibited a clinical sensitivity of 98% and a clinical specificity of 100%, indicating its reliability and accuracy for HPV genotyping. The multiplex real-time PCR assay is a cost-effective and efficient tool for HPV screening, detecting multiple genotypes simultaneously. It enhances screening efficiency and accuracy, improving early detection and management of HPV-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.